Evaluation of MRI for Prostate Cancer
Terminated
- Conditions
- Prostatic Neoplasms
- Registration Number
- NCT00930748
- Lead Sponsor
- Sheba Medical Center
- Brief Summary
The objective of this study is to evaluate imaging quality and correlation with histopathology in prostate cancer.
- Detailed Description
The objective of this study is to evaluate of the potential of endorectal 3T MRI for the staging of prostate cancer before prostatectomy or recurrence of prostate cancer after prostatectomy
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
- Age of patients: up to 80 years.
- Men scheduled for radical prostatectomy due to prostate cancer or men post radical prostatectomy with suspicion of recurrence.
- Patients who are able and willing to give consent and able to have an MRI examination.
Exclusion Criteria
- Contraindications to MRI including: claustrophobia, weight over 120 kg, implanted ferromagnetic materials or foreign objects, and known intolerance to the MRI contrast agent (e.g. Gadolinium or Dotarem)
- Individuals who are not able or willing to tolerate the required prolonged stationary supine position during imaging (approximately 1 hr.)
- Any rectal pathology preventing probe insertion, (as active proctitis, active ulcerative colitis, fissure ani)
- Any spinal pathology that prohibits maintaining supine position for an hour
- Patients with documented myocardial infarction within one month of protocol entry, and patients with cardiac pacemakers
- Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • MRI and pathology correlation 2 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does endorectal 3T MRI utilize to stage prostate cancer accurately?
How does endorectal MRI compare to standard-of-care imaging techniques in detecting prostate cancer recurrence?
Which biomarkers correlate with improved imaging outcomes in endorectal 3T MRI for prostate cancer staging?
What are the potential adverse events associated with endorectal 3T MRI in prostate cancer patients?
Are there combination imaging approaches that enhance endorectal MRI's efficacy in prostate cancer management?
Trial Locations
- Locations (1)
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Sheba Medical Center🇮🇱Ramat Gan, Israel